Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (NCT07291635)
A Randomized, Observer-Blind, Adaptive, Active Comparator-Controlled, Dose-Ranging, Multicenter, Safety, Tolerability, and Immunogenicity Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine in Adults 18 Years of Age and Older
🩺 Plain-English Summary (8th-Grade Level)
This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.
Who can join: Review the eligibility criteria below.
Location: Canadian Center for Vaccinology (CCfV) - IWK Health — Halifax, Nova Scotia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Canadian Center for Vaccinology (CCfV) - IWK Health — Halifax, Nova Scotia
- Montreal Heart Institute — Montreal, Quebec
- Vaccine Study Centre of McGill University Health Centre — Pierrefonds, Quebec
- CHU de Québec - Université Laval — Québec, Quebec
- Diex Recherche - Sherbrooke — Sherbrooke, Quebec
- Diex Recherche - Trois-Rivières — Trois-Rivières, Quebec
- Diex Recherche - Victoriaville — Victoriaville, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Influenza
- Kaiser Colorado Flu Nudge — Aurora, Colorado
- B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults — Birmingham, Alabama
- A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza — Anniston, Alabama
- Influenza IMPRINT Cohort: Defining the Impact of Initial Influenza Exposure on Immunity in Infants — Cincinnati, Ohio
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults — San Bernardino, California
Explore by condition: All Influenza clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.